Between September 2025 and June 2026, the FDA sent dozens of warning letters to online sellers and telehealth companies marketing compounded GLP-1 products. Those letters are unusually useful to patients, because they name the specific practices regulators found objectionable — which means you can check any platform against the same list. Here is what was cited, and how to spot it on a website in five minutes.
What regulators actually did
- In September 2025 the FDA issued more than 55 warning letters to online sellers of compounded GLP-1 products.
- During the week of 15 June 2026 it issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims, with reporting describing 30 letters across the action.
- It cited marketing that falsely suggests compounded GLP-1s are identical to approved products.
- It cited misrepresentation of sourcing.
- It separately warned about fraudulent compounded semaglutide and tirzepatide carrying false information on the product label.
Why this matters to you as a patient
Warning letters are not abstract regulatory housekeeping. They describe the exact sales practices that led patients to believe they were buying something other than what they received. Every practice named below is one you can check for yourself before handing over payment details.
Red flag one: 'the same as' claims
This is the practice regulators have targeted most consistently. Marketing that describes a compounded product as identical to, the same as, or equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro is making a claim the FDA has repeatedly acted against.
The molecule is intended to be the same. The manufacturing process, quality control, batch testing, and regulatory review are not. A compounded product has not been reviewed by any regulator for safety, efficacy, or manufacturing consistency.
Honest platforms say this plainly. Several in our review set state outright that compounded drug products are not FDA-approved. That single sentence is a meaningful signal about how a company treats its patients.
Red flag two: sourcing you cannot verify
Misrepresentation of sourcing was specifically cited in the FDA's actions. In practice, most platforms do not misrepresent sourcing so much as decline to discuss it — which produces the same result for the patient, who cannot check anything.
The public record is genuinely usable if you have a name. The FDA publishes compounding inspection findings, Form 483 observations, and recall notices. A patient who knows their pharmacy can look up whether it has been inspected, what was found, and whether products have been recalled.
A patient who does not know the name can do none of that. Ask directly, and treat evasion as informative.
Red flag three: pricing that is not the price
This is not an FDA matter but it is the most common way patients are misled in practice, and it has a clinical consequence rather than merely a financial one.
| Pattern | How to check |
|---|---|
| Membership fee stacked on medication | Ask whether the advertised figure includes clinical care |
| Introductory rate expiring upward | Ask what the price becomes in month two and month four |
| Dose ladder raising cost as you titrate | Ask what a maintenance dose costs, not a starting dose |
| Supplies and shipping billed separately | Ask whether syringes and delivery are included |
| Prepaid plans required for advertised rates | Ask what month-to-month actually costs |
The clinical consequence is that patients who budget from a misleading figure often stop treatment when the real cost arrives — typically around the point titration is starting to work, and food noise returns within weeks of stopping.
Red flag four: guaranteed approval
Any platform implying you will be approved before evaluating you is not evaluating you. A clinician who never declines anyone is not exercising clinical judgement, and that matters more for GLP-1s than for most medications.
Intrusive food thoughts overlap substantially with binge eating disorder, anxiety-driven eating, and medication side effects. Those need different treatment, and only a genuine assessment will catch them. A platform designed to approve everyone will simply prescribe.
Conversely, platforms that state prescription access depends on qualifying medically, or that patients are sometimes declined, are demonstrating that a real gate exists.
A five-minute checklist
- 1
Search the site for 'FDA-approved'
Does the platform state clearly that compounded products are not FDA-approved, or does it imply equivalence with brand-name drugs? The honest ones say it plainly.
- 2
Look for a named pharmacy
Is the compounding facility identified anywhere? If not, ask before enrolling and search the FDA's compounding inspections page for whatever name you are given.
- 3
Find the maintenance-dose price
Not the introductory rate, not the starting dose. What will you pay in month six at a working dose, including every fee?
- 4
Check for approval guarantees
Does the marketing suggest everyone qualifies? Genuine clinical gatekeeping means some people are declined, and platforms that acknowledge this are behaving better.
- 5
Look for urgency tactics
Countdown timers and limited-time framing on prescription medication tell you how the business thinks about patients.
Key Takeaways
- →The FDA issued more than 55 warning letters in September 2025 and around 30 more in June 2026 to GLP-1 telehealth sellers.
- →The most-cited practice was falsely suggesting compounded products are identical to FDA-approved ones.
- →Misrepresentation of sourcing was specifically named, and most platforms simply decline to discuss it.
- →FDA compounding inspection and recall records are usable — but only if you know your pharmacy's name.
- →Misleading pricing is the most common practical harm, and it causes patients to stop treatment mid-titration.
- →Guaranteed approval means nobody is screening for binge eating, anxiety, or contraindications.
Frequently Asked Questions
How many warning letters has the FDA issued?+
More than 55 to online sellers of compounded GLP-1 products in September 2025, and a further 25 to telehealth companies during the week of 15 June 2026, with reporting describing 30 letters across that action.
What exactly did the FDA object to?+
Marketing that falsely suggests compounded GLP-1s are identical to FDA-approved products, and misrepresentation of sourcing. It has separately warned about fraudulent compounded products carrying false information on their labels.
Does a warning letter mean a platform is unsafe?+
It means regulators found its promotional claims false or misleading, which is about how the product was sold rather than necessarily what was in it. It is still a meaningful signal about how a company treats the people buying from it.
How do I check a pharmacy's record?+
The FDA publishes compounding inspection findings, Form 483 observations, and recall notices. If you know your pharmacy by name you can look all of that up. If your platform will not tell you the name, you cannot — which is why asking matters.
Why is misleading pricing a clinical problem?+
Because patients who budget from a misleading figure often stop treatment when the real cost arrives, and that typically happens around the point titration is starting to work. Food noise returns within weeks of stopping, so the financial deception produces a clinical setback.
What is the single best question to ask a platform?+
Which pharmacy compounds my medication, and what will I pay per month at a maintenance dose including every fee? A platform that answers both clearly is behaving better than most of this market.
Looking for a provider?
We have reviewed 167 GLP-1 providers and ranked them by category:
Related Reading
This article is educational content, not medical advice. GLP-1 medications require a prescription and clinical supervision — talk to a licensed clinician about whether treatment is appropriate for you. See our medical disclaimer.